EcoDrugPlus

Beta-Secretase 1

Ensembl ID : ENSCHYG00000003314
Gene Symbol: BACE1
1 Cross references
220 Possible Orthologues:

Bradykinin Receptor B1

Ensembl ID : ENSCHYG00000024385
Gene Symbol: BDKRB1
1 Cross references
149 Possible Orthologues:

Butyrylcholinesterase

Ensembl ID : ENSCHYG00000014126
Gene Symbol: BCHE
1 Cross references
130 Possible Orthologues:

Calcitonin Receptor Like Receptor

Ensembl ID : ENSCHYG00000015594
Gene Symbol: CALCRL
1 Cross references
149 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSCHYG00000007820
Gene Symbol: CASR
1 Cross references
203 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSCHYG00000018295
Gene Symbol: CACNA2D1
1 Cross references
287 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSCHYG00000025204
Gene Symbol: CACNA2D2
1 Cross references
269 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSCHYG00000024210
Gene Symbol: CACNA2D3
1 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 1

Ensembl ID : ENSCHYG00000001745
Gene Symbol: CACNB1
1 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSCHYG00000020467
Gene Symbol: CACNB2
1 Cross references
206 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSCHYG00000006420
Gene Symbol: CACNB3
1 Cross references
278 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSCHYG00000023861
Gene Symbol: CACNB4
1 Cross references
251 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).